Featured Research

from universities, journals, and other organizations

Study of COX-2 inhibitors could lead to new class of stroke drugs

October 4, 2011
Stanford University Medical Center
A new study in mice points toward potential new therapies for stroke, a leading cause of death and foremost single cause of severe neurological disability. The study also may reveal why a much-heralded class of blockbuster drugs failed to live up to their promise.

A study, in mice, by investigators at the Stanford University School of Medicine points toward potential new therapies for stroke, a leading cause of death and foremost single cause of severe neurological disability. The study, which will be published online Oct. 3 in the Journal of Clinical Investigation, also may reveal why a much-heralded class of blockbuster drugs failed to live up to their promise.

Related Articles

Medical experts were excited when over a decade ago a class of drugs called COX-2-selective inhibitors came along. These new drugs were supposed to retain the advantages of aspirin and other so-called non-steroidal anti-inflammatory drugs, or NSAIDs, without causing stomach damage.

But in large-scale clinical trials of COX-2-selective inhibitors, puzzling -- and disturbing -- side effects emerged: namely, an increased risk of heart attacks and strokes. One already-approved drug in this category, rofecoxib (Vioxx), was pulled from the market in 2004. Another drug in this class is celecoxib, or Celebrex.

The new study helps explain why these drugs can be troublesome and how there may actually be some benefits to reap from the very molecular activity that these drugs were intended to block. "Some of what COX-2 does, it turns out, is good," said Katrin Andreasson, MD, associate professor of medicine and the study's senior author.

NSAIDs block both COX-2 and COX-1, two very similar versions of cyclo-oxygenase, an enzyme that catalyzes a key chemical reaction in the production of five related hormone-like messenger molecules called prostaglandins. The workings of COX-1 and COX-2 cause these five prostaglandin types to be produced in different ratios.

Prostaglandins travel from one cell to another, landing on and binding to dedicated receptor molecules sitting on cells' surfaces and stimulating various activities inside those cells. Each type of prostaglandin can trigger distinct effects. One prostaglandin in particular, PGE2, is known to be associated with pain and inflammation.

Because PGE2 is produced in relative abundance by COX-2 action, COX-2-selective inhibitors cause PGE2 levels to drop both absolutely and relative to the other prostaglandins. That makes them effective pain relievers. But Andreasson wanted to understand why they can cause strokes.

PGE2 has four separate counterpart receptors, designated EP1 through EP4, each of which sets in motion a different set of activities inside cells on binding to PGE2. Andreasson's team used a mouse model of stroke to show that activating one of these receptors, EP4, after a traumatic brain event such as a stroke can be very beneficial.

In the early 2000s, Andreasson carried out studies indicating that COX-2 activity is normally quite strong in nerve cells, where it appears to be involved in physiological changes underpinning learning. Now, in the new study, she and her colleagues found that amounts of EP4 on both nerve cells and the endothelial cells that line the blood vessels of the brain increase substantially after a stroke.

"This, to us, suggested that the EP4 receptor may be doing something important," she said.

Andreasson's team employed a compound that selectively binds to and activates EP4 to show that administering this compound by injection as much as three hours after a stroke reduced the amount of brain damage the mice suffered. Importantly, a single injection of this compound three hours after a stroke enhanced mice's behavioral recovery from the stroke, as measured a full week later by their superior performance on a test of motor coordination.

The researchers then examined the independent effects of EP4 activation on nerve cells and endothelial cells. Adding the compound increased the survival of nerve cells in a dish after the cells had been stressed by conditions similar to a stroke. In endothelial cells, EP4 activation by the compound resulted in an increased production of nitric oxide, a key chemical that among other things diffuses to nearby smooth muscle cells surrounding blood vessels, relaxing them. This lets the blood vessels dilate, enhancing blood flow.

Inactivation, via a sophisticated genetic manipulation, of the EP4 receptor on the mice's nerve cells both increased stroke severity in the mice and worsened their recovery. Similarly inactivating the receptor on endothelial cells worsened stroke injury and decreased blood flow to the affected area.

The only currently approved drug for stroke is tissue plasminogen activator, or tPA, which dissolves clots that prevent oxygenated blood from reaching brain tissue. But tPA does nothing to counter the damage caused after the stroke by inflammatory agents that flood into the affected tissue. New treatments for this debilitating disorder are desperately needed, Andreasson said. A drug that increased blood flow from still-functioning vasculature to the stroke region, as the EP4-activating compound does, might complement tPA's effect, she added.

"We showed that activating this single receptor, EP4, three hours after a stroke not only diminishes the volume of a mouse's affected brain tissue but also enhances the mouse's functional recovery," said Andreasson. "And we've taken this a step further by diligently unraveling the mechanisms by which that happens."

Andreasson's laboratory is now exploring the behavioral recovery of mice given the EP4-activating compound after longer post-stroke waiting times. She said she wants to see whether the therapeutic window can be extended to more than six hours after a stroke, which could greatly increase the value of such a treatment.

Andreasson cautioned that many therapies, even when highly successful in mice, fail in the clinic.

The National Institutes of Health, American Heart Association, and Weston-Havens Foundation funded this study. Co-authors in addition to the study's first author, research associate Xibin Liang, MD, PhD, include postdoctoral researchers Lu Lin, MD, PhD, and Tingting Pan, PhD; graduate students Nathaniel Woodling and Christoph Anacker; and research assistants Qian Wang and Milton Merchant. All are associated with Andreasson's laboratory.

Story Source:

The above story is based on materials provided by Stanford University Medical Center. The original article was written by Bruce Goldman. Note: Materials may be edited for content and length.

Journal Reference:

  1. Xibin Liang, Lu Lin, Nathaniel S. Woodling, Qian Wang, Christoph Anacker, Tingting Pan, Milton Merchant, Katrin Andreasson. Signaling via the prostaglandin E2 receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI46279

Cite This Page:

Stanford University Medical Center. "Study of COX-2 inhibitors could lead to new class of stroke drugs." ScienceDaily. ScienceDaily, 4 October 2011. <www.sciencedaily.com/releases/2011/10/111003131412.htm>.
Stanford University Medical Center. (2011, October 4). Study of COX-2 inhibitors could lead to new class of stroke drugs. ScienceDaily. Retrieved October 26, 2014 from www.sciencedaily.com/releases/2011/10/111003131412.htm
Stanford University Medical Center. "Study of COX-2 inhibitors could lead to new class of stroke drugs." ScienceDaily. www.sciencedaily.com/releases/2011/10/111003131412.htm (accessed October 26, 2014).

Share This

More Mind & Brain News

Sunday, October 26, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Academic Scandal Shocks UNC

Academic Scandal Shocks UNC

AP (Oct. 23, 2014) A scandal involving bogus classes and inflated grades at the University of North Carolina was bigger than previously reported, a new investigation found. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Working Mother Getaway: Beaches Turks & Caicos

Working Mother Getaway: Beaches Turks & Caicos

Working Mother (Oct. 22, 2014) Feast your eyes on this gorgeous family-friendly resort. Video provided by Working Mother
Powered by NewsLook.com
What Your Favorite Color Says About You

What Your Favorite Color Says About You

Buzz60 (Oct. 22, 2014) We all have one color we love to wear, and believe it or not, your color preference may reveal some of your character traits. In celebration of National Color Day, Krystin Goodwin (@kyrstingoodwin) highlights what your favorite colors may say about you. Video provided by Buzz60
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins